Acyclovir has been considered the treatment of choice for neonatal HSV disease since 1991
Interval
Neonates < 4 weeks with fever: Parenteral acyclovir (20 mg/kg IV q8hours) should be added empirically to antibiotics for neonates admitted with fever in the following
Acyclovir has been the treatment of choice for neonatal HSV disease since 1991
• Suppressive therapy with acyclovir for neonatal HSV or valganciclovir for symptomatic
Acyclovir Dose and Route Because of poor oral bioavailability, neonatal herpes must be treated with intravenous (IV) acyclovir at a dose of 60 mg/kg/day divided every 8 hours
3 to 4
9% in a 20 mL syringe = 125 mg in 25 mL = 5 mg/mL
• Recommend doses on the higher end of a medication’s dosing range Key Points 45 Beta-lactams Drug Standard Dosing ECMO Dosing Recommendations Ceftriaxone 1-2g q 24h or 2g q12h for meningitis Standard dosing Cefepime 1 g q6h or 1-2 g q8-12h 2 g over 3 hours every 8 hours Piperacillin/ tazobactam 3
Manifestations generally occur between the 1st and 3rd weeks of life but rarely may not appear until as late as the 4th week
HSV infections in the neonatal and pediatric populations range from uncomplicated mucocutaneous diseases to severe, life-threatening infections
Dose adjustments With systemic use: Consider dose reduction
[1] Although the incidence and mortality have declined over the past few
Among 14- to 49-year-old females, the prevalence of HSV-2 infection is 15
Seizure 3
current approved dosing regimen of acyclovir for neonatal HSV infection is 10 mg/kg every 8 hours for 10 days